Market Research Reports

Meningococcal Vaccines Market (Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

109pages
Published Date: 2014-04-28
 

Description


The global meningococcal vaccines market is studied on the basis of vaccine types such as polysaccharide, conjugate and combination vaccines. The vaccine types are further segmented into different brands. The report also highlights and analyzes various brands under pipeline segment, namely, Bexsero, MnB rLP2806 and NmVac-4DT. A detailed market analysis and forecast for these segments has been provided in this study, in terms of revenue (USD million) for the period 2011 to 2019. The report also provides the compounded annual growth rate (CAGR %) for each meningococcal vaccine segment and brand for the forecast period 2013 to 2019, while market size estimations have been made considering 2011 and 2012 as the base years. 

In terms of geographical distribution, the global meningococcal vaccines market has been classified into four major geographical areas, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The current and future market sizes (in terms of USD million) of the above regional markets have been provided in the report for the period 2011 to 2019 with their growth rate (%) for the period 2013 to 2019. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and flourish in the global meningococcal vaccines market. 

The market overview section of the report demonstrates the market dynamics and market trends such as drivers, restraints and opportunities that influence the current and future status of this industry. Impact factors such as market attractiveness analysis and Porter’s five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global meningococcal vaccines market.

The report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Sanofi S.A., Novartis International AG, GlaxoSmithKline plc, Pfizer, Inc., Serum Institute of India, Ltd., JN-International Medical Corporation, Nuron Biotech, Baxter International and Biomed Pvt. Ltd.

The global meningococcal vaccines market is segmented as follow:

Meningococcal Vaccines Market, by Type
  • Polysaccharide Vaccines, by Brand
    • Menomune
    • Mencevax
    • NmVac4
    • Others
      • Quadri Meningo
      • Bi Meningo
  • Conjugate Vaccines, by Brand
    • Menactra
    • Menveo
    • NeisVac-C
    • Nimenrix
    • Meningitec
    • Menjugate
    • MenAfriVac
  • Combination Vaccines, by Brand
    • MenHibrix
    • Menitorix
  • Pipeline Vaccines, by Brand
    • Bexsero
    • MnB rLP2806
    • NmVac4-DT
Meningococcal Vaccines Market, by Geography
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Table of Contents



Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Secondary Research
      1.3.2 Primary Research
1.4 List of Abbreviations
1.5 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Meningococcal Vaccines Market
2.2 Global Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)
2.3 Comparative Analysis: Global Meningococcal Vaccines Market, by Geography, 2012 & 2019 (Value %)

Chapter 3 Global Meningococcal Vaccines Market Overview
3.1 Introduction
      3.1.1 Meningococcal Disease
               3.1.1.1 Clinical Features
               3.1.1.2 Epidemiology
               3.1.1.3 Diagnosis & Treatment
      3.1.2 Types of Meningococcal Vaccines
3.2 Regulatory Scenario
3.3 Market Drivers
      3.3.1 Developing economies reshaping global health and development
      3.3.2 Education and awareness through various non-profit organizations
      3.3.3 Travel vaccines for meningococcal disease
3.4 Market Restraints
      3.4.1 Disparate age groups and dosage regimen for routine immunization, and unpredictable and dynamic epidemiology of meningococcal disease
      3.4.2 Maintenance of cold chains to deliver vaccines leading to high cost of vaccination
3.5 Market Opportunities
      3.5.1 Development of vaccines through collaborations and public private partnerships making vaccines more affordable
      3.5.2 Novel approaches to improve the stability of meningococcal vaccines
      3.5.3 Developing halal vaccines
3.6 Porter’s Five Force Analysis for the Global Meningococcal Vaccines Market
      3.6.1 Bargaining Power of Suppliers
      3.6.2 Bargaining Power of Buyers
      3.6.3 Threat of Substitutes
      3.6.4 Threat of New Entrants
      3.6.5 Competitive Rivalry
3.7 Market Attractiveness Analysis for the Global Meningococcal Vaccines Market, by Geography

Chapter 4 Global Meningococcal Vaccines Market, by Type
4.1 Introduction
      4.1.1 Global Meningococcal Vaccines Market Revenue, by Type, 2011 - 2019 (USD Million)
4.2 Comparative Analysis: Global Meningococcal Vaccines Market, by Type, 2012 & 2018 (Value %)
4.3 Polysaccharide Meningococcal Vaccines
      4.3.1 Global Polysaccharide Vaccines Market Revenue, by Brand, 2011 - 2019 (USD Million)
      4.3.2 Menomune
              4.3.2.1 Global Menomune Market Revenue, 2011 - 2019 (USD Million)
      4.3.3 Mencevax
              4.3.3.1 Global Mencevax Market Revenue, 2011 – 2014 (USD Million)
      4.3.4 NmVac4-A/C/Y/W-135
              4.3.4.1 Global NmVac4 Market Revenue, 2011 – 2015 (USD Million)
      4.3.5 Others (Bi Meningo, Quadri Meningo)
              4.3.5.1 Global Other Polysaccharide Vaccines Market Revenue, 2011 – 2019 (USD Million)
4.4 Conjugate Meningococcal Vaccines
      4.4.1 Global Conjugate Vaccines Market Revenue, by Brand, 2011 - 2019
      4.4.2 Menactra
              4.4.2.1 Global Menactra Market Revenue, 2011 - 2019 (USD Million)
      4.4.3 Menveo
              4.4.3.1 Global Menveo Market Revenue, 2011 - 2019 (USD Million)
      4.4.4 NeisVac-C
              4.4.4.1 Global NeisVac-C Market Revenue, 2011 - 2019 (USD Million)
      4.4.5 Nimenrix
              4.4.5.1 Global Nimenrix Market Revenue, 2012 - 2019 (USD Million)
      4.4.6 Meningitec
              4.4.6.1 Global Meningitec Market Revenue, 2011 - 2019 (USD Million)
      4.4.7 Menjugate (Meningococcal Group C- CRM197 Conjugate Vaccine)
              4.4.7.1 Global Menjugate Market Revenue, 2011 - 2019 (USD Million)
      4.4.8 MenAfriVac
              4.4.8.1 Global MenAfriVac Market Revenue, 2011 - 2019 (USD Million)
4.5 Combination Meningococcal Vaccines
      4.5.1 Global Combination Vaccines Market Revenue, by Brand, 2011 - 2019 (USD Million)
      4.5.2 MenHibrix
              4.5.2.1 Global MenHibrix Market Revenue, 2013 - 2019 (USD Million)
      4.5.3 Menitorix
              4.5.3.1 Global Menitorix Market Revenue, 2011 - 2019 (USD Million)
4.6 Pipeline Analysis
      4.6.1 Global Meningococcal Vaccines Market Pipeline Forecast, by Brand, 2011 - 2019 (USD Million)
      4.6.2 Bexsero
              4.6.2.1 Global Bexsero Market Revenue, 2013 - 2019 (USD Million)
      4.6.3 MnB rLP2806
              4.6.3.1 Global MnB rLP2806 Market Revenue, 2017 - 2019 (USD Million)
      4.6.4 NmVac4-A/C/Y/W-135-DT
              4.6.4.1 Global NmVac4 DT Market Revenue, 2015 - 2019 (USD Million)

Chapter 5 Global Meningococcal Vaccines Market, by Geography
5.1 Introduction
      5.1.1 Global Meningococcal Vaccines Market Revenue, by Geography, 2011 - 2019 (USD Million)
5.2 North America
      5.2.1 North America Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)
5.3 Europe
      5.3.1 Europe Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)
5.4 Asia-Pacific
      5.4.1 Asia-Pacific Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)
5.5 Rest of the World
      5.5.1 Rest of the World Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)

Chapter 6 Competitive Landscape
6.1 Market Share by Key Players, 2012 (Value %)
      6.1.1 Methodology
      6.1.2 Analysis

Chapter 7 Recommendations
7.1 Focus on Low Cost of Manufacturing
7.2 Developing Animal Component Free and Halal Vaccines
7.3 Tapping Emerging Markets
7.4 Collaborating With Community Pharmacies

Chapter 8 Company Profiles
8.1 Baxter International, Inc.
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
      8.1.5 Recent Developments
8.2 Biomed Pvt. Ltd.
      8.2.1 Company Overview
      8.2.2 Financial Overview
      8.2.3 Product Portfolio
      8.2.4 Business Strategies
      8.2.5 Recent Developments
8.3 GlaxoSmithKline plc
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
      8.3.5 Recent Developments
8.4 JN-International Medical Corporation
      8.4.1 Company Overview
      8.4.2 Financial Overview
      8.4.3 Product Portfolio
      8.4.4 Business Strategies
      8.4.5 Recent Developments
8.5 Novartis International AG
      8.5.1 Company Overview
      8.5.2 Financial Overview
      8.5.3 Product Portfolio
      8.5.4 Business Strategies
      8.5.5 Recent Developments
8.6 Nuron Biotech, Inc.
      8.6.1 Company Overview
      8.6.2 Financial Overview
      8.6.3 Product Portfolio
      8.6.4 Business Strategies
      8.6.5 Recent Developments
8.7 Pfizer, Inc.
      8.7.1 Company Overview
      8.7.2 Financial Overview
      8.7.3 Product Portfolio
      8.7.4 Business Strategies
      8.7.5 Recent Developments
8.8 Sanofi SA
      8.8.1 Company Overview
      8.8.2 Financial Overview
      8.8.3 Product Portfolio
      8.8.4 Business Strategies
      8.8.5 Recent Developments
8.9 Serum Institute of India Ltd.
      8.9.1 Company Overview
      8.9.2 Financial Overview
      8.9.3 Product Portfolio
      8.9.4 Business Strategies
      8.9.5 Recent Developments

List of Figures

FIG.1 Global Meningococcal Vaccines Market Segmentation
FIG.2 Global Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)
FIG.3 Comparative Analysis: Global Meningococcal Vaccines Market, by Geography, 2012 & 2019 (Value %)
FIG.4 Risk Factors for Meningococcal Disease
FIG.5 Clinical Manifestations of Meningococcal Disease
FIG.6 Porter’s Five Forces Analysis: Global Meningococcal Vaccines Market
FIG.7 Market Attractiveness Analysis: Global Meningococcal Vaccines Market, by Geography
FIG.8 Comparative Analysis: Global Meningococcal Vaccines Market, by Type, 2012 & 2019 (Value %)
FIG.9 Global Menomune Market Revenue, 2011 – 2019 (USD Million)
FIG.10 Global Mencevax Market Revenue, 2011 – 2014 (USD Million)
FIG.11 Global NmVac4 Market Revenue, 2011 – 2015 (USD Million)
FIG.12 Global Other Polysaccharide Vaccines Market Revenue, 2011 – 2019 (USD Million)
FIG.13 Global Menactra Market Revenue, 2011 – 2019 (USD Million)
FIG.14 Global Menveo Market Revenue, 2011 – 2019 (USD Million)
FIG.15 Global NeisVac-C Market Revenue, 2011 – 2019 (USD Million)
FIG.16 Global Nimenrix Market Revenue, 2012 – 2019 (USD Million)
FIG.17 Global Meningitec Market Revenue, 2011 – 2019 (USD Million)
FIG.18 Global Menjugate Market Revenue, 2011 – 2019 (USD Million)
FIG.19 Global MenAfriVac Market Revenue, 2011 – 2019 (USD Million)
FIG.20 Global MenHibrix Market Revenue, 2013 – 2019 (USD Million)
FIG.21 Global Menitorix Market Revenue, 2011 – 2019 (USD Million)
FIG.22 Global Bexsero Market Revenue, 2013 – 2019 (USD Million)
FIG.23 Global MnB rLP2806 Market Revenue, 2017 – 2019 (USD Million)
FIG.24 Global NmVac4 DT Market Revenue, 2015 – 2019 (USD Million)
FIG.25 North America Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)
FIG.26 Europe Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)
FIG.27 Asia-Pacific Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)
FIG.28 Rest of the World Meningococcal Vaccines Market Revenue, 2011 – 2019 (USD Million)
FIG.29 Market Share Analysis: Meningococcal Vaccines Market, 2012 (Value %)
FIG.30 Baxter International, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG.31 GlaxoSmithKline plc: Annual Revenue, 2010 – 2012 (USD Million)
FIG.32 Novartis International AG: Annual Revenue, 2010 – 2012 (USD Million)
FIG.33 Pfizer, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG.34 Sanofi SA: Annual Revenue, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global Meningococcal Vaccines Market
TABLE 3 Global Meningococcal Vaccines Market Revenue, by Type, 2011 - 2019 (USD Million)
TABLE 4 Global Polysaccharide Vaccines Market Revenue, by Brand, 2011 – 2019 (USD Million)
TABLE 5 Global Conjugate Vaccines Market Revenue, by Brand, 2011 – 2019 (USD Million)
TABLE 6 Global Combination Vaccines Market Revenue, by Brand, 2011 - 2019 (USD Million)
TABLE 7 Global Meningococcal Vaccines Market Pipeline Forecast, by Brand, 2011 - 2019 (USD Million)
TABLE 8 Global Meningococcal Vaccines Market Revenue, by Geography, 2011 - 2019 (USD Million)

Enquiry Before Buying


Free Market Analysis


Meningococcal disease caused by the bacterium Neisseria meningitidis is a life threatening condition which severely infects the meninges or the thin lining surrounding the brain and the spinal cord. Five out of many serogroups of the bacterium are responsible for the invasive meningococcal disease. These serogroups are predominantly present only in humans in the dormant state and may eventually cause the diseased condition due to environmental or immunogenic factors. The disease is known to be contagious and its consequences can be fatal within 24 hours from the onset of symptoms. Prevalence of the serogroups responsible for the disease varies with age, time and geographical locations. 

The global meningococcal vaccines market is segmented broadly into polysaccharide, conjugate and combination vaccines. These vaccine types are further segmented into different brands available in the market. Polysaccharide vaccines is the oldest type available in market since last three decades. However, the presence and widespread use of conjugate vaccines has drastically reduced the incidences of bacterial meningitis due to the prolonged immunity achieved against the disease-causing serogroups, unlike polysaccharide vaccines which provide immunity for a very short period. Combination vaccines against invasive meningococci in combination with other organisms such as pneumococcal and Haemophilus influenzae type B are considered as new weapons to fight against two bacterial infections. This has shown to reduce the number of injections needed to be administered when compared to their individual doses. Hence, combination vaccines are likely to have high growth in forthcoming years.

The notable pipeline vaccines against meningococcal disease include Bexsero by Novartis, MnB rLP2806 by Pfizer and NmVac4-DT by JN International Medical Corporation. Novartis in January 2013, received marketing authorization for Bexsero as the only vaccine against serogroup B, across the European Union, Canada and Australia, and has been currently filed for U.S. FDA licensure. The rLP2806 vaccine, is currently in phase III clinical trials and has been granted Breakthrough Therapy Status by the U.S. FDA in 2014. NmVac4 DT, on the other hand, has been developed against the broad range of (quadrivalent) serogroups A, C, Y and W-135. Moreover, its manufacturer of the vaccine JN International Medical Corporation claims the vaccine to be animal component free, which is expected to be the major driver for its demand post market launch.

Major growth drivers for the global meningococcal vaccines market include favourable public-private partnerships to support development of vaccines at low cost, and the medical emergency status of the disease. Increase in the demand for vaccines and number of people getting immunized has been majorly contributed to the education and awareness campaigns conducted by manufacturers as well as non-profit organizations in the developed economies. Government intervention such as approval of legislations to mandate immunization programs for school children up to a certain age, and stringent regulations for Hajj pilgrims and sub-Saharan travellers also contribute positively to this market due to increased demand for these vaccines from the non-profit organizations.

Geographically, Asia Pacific is expected to be the fastest growing market followed by Rest of the World (RoW) during the forecast period. The continuous growth in the population base and the cyclic occurrences of meningococcal disease outbreaks in past is likely to drive the market due to rising focus on preventive measure against the dreadful disease. The onset of recent trends such as enrolment of pharmacists in training programs conducted by New Zealand Ministry of Health are also contributing to the growth of the market. In North America and Europe, due to government intervention with respect to legislations, immunization programs and awareness campaigns incidences of meningitis have reduced to a large extent. According to a report by the U.S. Centers for Disease Control and Prevention (CDC) 1,000 to 2,600 people contract meningococcal disease each year in the United States, whereas in Africa, it is estimated to be 1,000 cases per one lakh population. 

The key players contributing to the global meningococcal vaccines market include Sanofi SA, Novartis AG, GSK plc, Pfizer, Inc., Nuron Biotech, JN International Medical Corporation, Serum Institute of India Ltd., Baxter International and Biomed Pvt. Ltd.

global-meningococcal-vaccines-market-2011-2019
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research